Wall Street brokerages expect Dynavax Technologies Co. (NASDAQ: TWO – Get Rating) to post $ 146.70 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Dynavax Technologies’ earnings. The highest sales estimate is $ 146.72 million and the lowest is $ 146.68 million. Dynavax Technologies reported sales of $ 52.77 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 178%. The firm is scheduled to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Dynavax Technologies will report full-year sales of $ 653.10 million for the current year, with estimates ranging from $ 649.50 million to $ 656.69 million. For the next financial year, analysts forecast that the company will report sales of $ 298.76 million, with estimates ranging from $ 136.40 million to $ 461.12 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that provide coverage for Dynavax Technologies.
Dynavax Technologies (NASDAQ: TWO – Get Rating) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported $ 0.22 EPS for the quarter, missing the consensus estimate of $ 0.24 by ($ 0.02). Dynavax Technologies had a net margin of 23.12% and a return on equity of 87.36%. The business had revenue of $ 113.99 million for the quarter, compared to the consensus estimate of $ 117.76 million. During the same period in the prior year, the business posted $ 0.01 EPS.
Several equities research analysts have weighed in on DVAX shares. The Street raised shares of Dynavax Technologies from a “d +” rating to a “c” rating in a research report on Wednesday, March 30th. StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, May 12th. Finally, Zacks Investment Research cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, March 1st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $ 21.00.
DVAX stock opened at $ 12.12 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.85 and a current ratio of 2.02. Dynavax Technologies has a 52 week low of $ 7.26 and a 52 week high of $ 21.39. The firm’s fifty day moving average is $ 10.32 and its 200 day moving average is $ 12.16. The firm has a market cap of $ 1.53 billion, a P / E ratio of 22.04 and a beta of 1.41.
In related news, insider Justin Burgess sold 6,000 shares of Dynavax Technologies stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $ 10.00, for a total transaction of $ 60,000.00. Following the completion of the transaction, the insider now directly owns 3,854 shares of the company’s stock, valued at approximately $ 38,540. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 9.31% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. increased its stake in Dynavax Technologies by 498.0% during the 1st quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock valued at $ 26,000 after purchasing an additional 1,967 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of Dynavax Technologies by 940.7% in the first quarter. Quantbot Technologies LP now owns 2,508 shares of the company’s biopharmaceutical stock worth $ 27,000 after acquiring an additional 2,267 shares during the period. Signaturefd LLC grew its stake in shares of Dynavax Technologies by 12,690.7% in the first quarter. Signaturefd LLC now owns 5,500 shares of the company’s biopharmaceutical stock worth $ 60,000 after acquiring an additional 5,457 shares during the period. Rockefeller Capital Management LP bought a new stake in shares of Dynavax Technologies in the third quarter worth approximately $ 163,000. Finally, Maverick Capital Ltd. bought a new stake in shares of Dynavax Technologies in the third quarter worth approximately $ 176,000. Institutional investors and hedge funds own 76.80% of the company’s stock.
About Dynavax Technologies (Get Rating)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for the prevention of infection caused by all known subtypes of hepatitis B virus in the age of 18 years and older in the United States and Europe.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analyzes’ ratings for Dynavax Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.